Glucagon-Like Peptide-1 Receptor Agonist-Experienced Adults with Type 2 Diabetes Switching to Once-Weekly Semaglutide in a Real-World Setting: SURE Program Post Hoc Analysis.

ABSTRACT:

Introduction

To investigate outcomes in adults with type 2 diabetes who switched to once-weekly (OW) semaglutide from another glucagon-like peptide-1 receptor agonist (GLP-1RA) in clinical practice.

Methods

This post hoc analysis used data from the SemaglUtide Real-world Evidence (SURE) program, which included nine observational studies investigating the initiation of OW semaglutide in people with type 2 diabetes in routine clinical practice. Using a random coefficient-adjusted mixed model for repeated measurements, changes in glycosylated hemoglobin (HbA_1c), body weight, and body mass index were analyzed for GLP-1RA-experienced patients who had at least one documented HbA_1c value within the 12 weeks before switching to OW semaglutide. In addition, desc

SUBMITTER: Rudofsky G 

PROVIDER: S-EPMC11787244 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature